Skip to main content
Clinical Trials/NCT05897658
NCT05897658
Not yet recruiting
Phase 3

Pilot Study: Levetiracetam Prophylaxis Randomized Controlled Trial in Brain Tumor Resection

Hamilton Health Sciences Corporation0 sites70 target enrollmentMarch 2025

Overview

Phase
Phase 3
Intervention
Levetiracetam
Conditions
Seizures
Sponsor
Hamilton Health Sciences Corporation
Enrollment
70
Primary Endpoint
Recruitment Rate
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

This study aims to evaluate feasibility of a double-blind randomized controlled trial for levetiracetam prophylaxis for prevention of seizure in the perioperative phase of brain tumor resection.

Registry
clinicaltrials.gov
Start Date
March 2025
End Date
March 2026
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Adult age 18 years or older
  • Undergoing craniotomy for a brain tumor
  • Intra-axial tumor location
  • Supratentorial tumor location

Exclusion Criteria

  • Documented seizure history or epilepsy diagnosis
  • Currently taking an antiepileptic medication
  • Unable to take levetiracetam (e.g. allergy, inability to swallow)
  • Inability to obtain consent from participant or substitute decision maker prior to surgery
  • Renal impairment with eGFR less than 50
  • Pregnancy

Arms & Interventions

Seizure Prophylaxis (Levetiracetam)

Levetiracetam 1 g taken orally twice a day for 7 days

Intervention: Levetiracetam

Placebo

Placebo taken orally twice a day for 7 days

Intervention: Placebo

Outcomes

Primary Outcomes

Recruitment Rate

Time Frame: Through study completion, approximately 1 year

Feasibility outcome

Secondary Outcomes

  • Fraction of eligible patients approached(Through study completion, approximately 1 year)
  • Fraction of approached patients consent(Through study completion, approximately 1 year)
  • Role of individual who approached patients(Through study completion, approximately 1 year)
  • Protocol adherence(Through study completion, approximately 1 year)
  • Adverse events(Through study completion, approximately 1 year)
  • Unblinding events(Through study completion, approximately 1 year)

Similar Trials